Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Breast Cancer Res Treat ; 16(1): 41-50, 1990 Jul.
Article in English | MEDLINE | ID: mdl-2169927

ABSTRACT

The purpose of this study was to characterize breast carcinomas by cell kinetic parameters. Mitotic rate (MR) and flow cytometrically (FCM) measured cell cycle distribution as well as chromatin testing in situ employing heparin for determination of activated chromatin, provided the following results: MR counted in 73 unselected carcinomas showed an increase up to a tumor size of 4.2 cm (p less than 0.05); beyond this diameter, the MR was found to decrease. In T1-T2 carcinomas, cell cycle stage analysis yielded higher percentages of cells in S and G2M phase for ductal (13% and 12%, N = 22) than for lobular (8% and 7%, N = 8) node-negative carcinomas (p less than 0.002). In ductal carcinomas, lymph node involvement was reflected by higher % G2M values (15%, N = 26) compared with negative cases (12%, N = 22) (p less than 0.05). Ductal node-positive T3-T4 carcinomas (N = 10) revealed a higher % S value (16%) than their T1-T2 counterparts. A correlation between MR and % G2M was established only up to a tumor size of 4.2 cm (r = 0.39, p less than 0.05). A highly sensitive ('H') and a poorly sensitive ('P') subgroup of carcinomas with respect to heparin-induced changes in fluorescence intensity of the G1/0 peak of the DNA aneuploid cell line were identified, as previously shown. These subgroups were here updated with a larger number of carcinomas and were limited to T1-T2 cancers (N = 57). Group 'H' included more younger patients (p less than 0.005), less cases with nodal involvement in ductal carcinomas (p less than 0.05), and lower % G2M values in lobular node-negative cases (p less than 0.05), than group 'P'. DNA diploid cells always existing in DNA aneuploid carcinomas are more sensitive than their aneuploid counterparts (p less than 0.01); however, they strengthen the stratification to 'H' and 'P'. We suggest 'H' carcinomas to be less aggressive than 'P' carcinomas. Small breast carcinomas are recommended to cell kinetic investigations for individualizing adjuvant therapy.


Subject(s)
Breast Neoplasms/pathology , Carcinoma/pathology , Adult , Age Factors , Aged , Aneuploidy , Breast Neoplasms/genetics , Carcinoma/genetics , Carcinoma, Intraductal, Noninfiltrating/genetics , Carcinoma, Intraductal, Noninfiltrating/pathology , Carcinosarcoma/genetics , Carcinosarcoma/pathology , Cell Cycle , Chromatin/drug effects , Chromatin/ultrastructure , DNA, Neoplasm/analysis , Female , Flow Cytometry , Heparin/pharmacology , Humans , Lymphatic Metastasis , Middle Aged , Risk
2.
Radiobiol Radiother (Berl) ; 31(2): 193-5, 1990.
Article in German | MEDLINE | ID: mdl-2356303

ABSTRACT

The record and verify system (EPS) answers the control and recording of carrying out irradiation. Connection between accelerator and personal computer is done by a process calculator. The EPS-programme runs at a personal computer and is written in TURBO-Pascal. A first realization will be done at linear accelerator NEPTUN 10p.


Subject(s)
Computer Systems , Particle Accelerators/standards , Germany, East , Humans
3.
Radiobiol Radiother (Berl) ; 31(5): 437-48, 1990.
Article in German | MEDLINE | ID: mdl-2277832

ABSTRACT

To increase the quality of radiotherapy a verify and record system (VPS) was developed for teletherapy equipments, that takes control of manually adjusted irradiation parameters and of recording all relevant data of radiotherapy. The VPS can be adapted to special wishes of the user and it lends itself to application on different irradiation equipments. In the represented paper especially the extent of efficiency of the system is shown which is characterized by high operating comfort, flexible reacting to exceptional cases and by high date and operating security. The testing phase on an accelerator model has been brought to a close, actually the system is installed to an electron linear accelerator "Neptun 10p" and led to clinical trial.


Subject(s)
Radiotherapy/instrumentation , Humans , Particle Accelerators/instrumentation , Quality Assurance, Health Care , Radiotherapy/methods , Technology, Radiologic
SELECTION OF CITATIONS
SEARCH DETAIL
...